Agomelatine for the treatment of major depressive disorder

Regina M. Carney, Richard C. Shelton

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Introduction: This article discusses agomelatine (Valdoxan /Thymanax ; Servier/Novartis), which is a melatonin (MT1/MT2) agonist and serotonin (5-HT2c) receptor antagonist. Agomelatine has been approved for the treatment of adults with major depression by several regulatory agencies and is now on the market in 41 countries. Areas covered: Literature related to agomelatine was reviewed on PubMed using the search terms 'agomelatine OR S-20098' and 204 articles were found. Twelve published, randomized, double-blind studies were included in this review. Expert opinion: Agomelatine produces strong effects on circadian sleep phase disturbances, improving time to sleep onset and quality of sleep. It has been shown to be superior to placebo and similar to existing antidepressants, as demonstrated by short-term clinical trials and one relapse prevention trial. However, 0 0.6% and 3 4.5% of patients treated with 25 and 50 mg, respectively, showed elevated transaminases. Although none of these reactions so far seem to have been serious, the adverse effects in the liver may present a regulatory and marketing challenge. Given equivalence or modest superiority to existing, generic alternatives, the acceptability in a third-party reimbursement environment is questionable. Future clinical trials are needed to establish an appropriate market niche.

Original languageEnglish
Pages (from-to)2411-2419
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number15
DOIs
StatePublished - Oct 1 2011
Externally publishedYes

Fingerprint

S 20098
Major Depressive Disorder
Sleep
Therapeutics
Clinical Trials
Expert Testimony
Melatonin
Secondary Prevention
Transaminases
Marketing
Double-Blind Method
PubMed
Antidepressive Agents

Keywords

  • Agomelatine
  • Antidepressant
  • Anxiety
  • Depression
  • Melatonin receptors
  • Serotonin receptors
  • Sleep

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Agomelatine for the treatment of major depressive disorder. / Carney, Regina M.; Shelton, Richard C.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 15, 01.10.2011, p. 2411-2419.

Research output: Contribution to journalArticle

Carney, Regina M. ; Shelton, Richard C. / Agomelatine for the treatment of major depressive disorder. In: Expert Opinion on Pharmacotherapy. 2011 ; Vol. 12, No. 15. pp. 2411-2419.
@article{335595702d7d40828da08a11c5aad433,
title = "Agomelatine for the treatment of major depressive disorder",
abstract = "Introduction: This article discusses agomelatine (Valdoxan ™/Thymanax ™; Servier/Novartis), which is a melatonin (MT1/MT2) agonist and serotonin (5-HT2c) receptor antagonist. Agomelatine has been approved for the treatment of adults with major depression by several regulatory agencies and is now on the market in 41 countries. Areas covered: Literature related to agomelatine was reviewed on PubMed using the search terms 'agomelatine OR S-20098' and 204 articles were found. Twelve published, randomized, double-blind studies were included in this review. Expert opinion: Agomelatine produces strong effects on circadian sleep phase disturbances, improving time to sleep onset and quality of sleep. It has been shown to be superior to placebo and similar to existing antidepressants, as demonstrated by short-term clinical trials and one relapse prevention trial. However, 0 0.6{\%} and 3 4.5{\%} of patients treated with 25 and 50 mg, respectively, showed elevated transaminases. Although none of these reactions so far seem to have been serious, the adverse effects in the liver may present a regulatory and marketing challenge. Given equivalence or modest superiority to existing, generic alternatives, the acceptability in a third-party reimbursement environment is questionable. Future clinical trials are needed to establish an appropriate market niche.",
keywords = "Agomelatine, Antidepressant, Anxiety, Depression, Melatonin receptors, Serotonin receptors, Sleep",
author = "Carney, {Regina M.} and Shelton, {Richard C.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1517/14656566.2011.607812",
language = "English",
volume = "12",
pages = "2411--2419",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "15",

}

TY - JOUR

T1 - Agomelatine for the treatment of major depressive disorder

AU - Carney, Regina M.

AU - Shelton, Richard C.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Introduction: This article discusses agomelatine (Valdoxan ™/Thymanax ™; Servier/Novartis), which is a melatonin (MT1/MT2) agonist and serotonin (5-HT2c) receptor antagonist. Agomelatine has been approved for the treatment of adults with major depression by several regulatory agencies and is now on the market in 41 countries. Areas covered: Literature related to agomelatine was reviewed on PubMed using the search terms 'agomelatine OR S-20098' and 204 articles were found. Twelve published, randomized, double-blind studies were included in this review. Expert opinion: Agomelatine produces strong effects on circadian sleep phase disturbances, improving time to sleep onset and quality of sleep. It has been shown to be superior to placebo and similar to existing antidepressants, as demonstrated by short-term clinical trials and one relapse prevention trial. However, 0 0.6% and 3 4.5% of patients treated with 25 and 50 mg, respectively, showed elevated transaminases. Although none of these reactions so far seem to have been serious, the adverse effects in the liver may present a regulatory and marketing challenge. Given equivalence or modest superiority to existing, generic alternatives, the acceptability in a third-party reimbursement environment is questionable. Future clinical trials are needed to establish an appropriate market niche.

AB - Introduction: This article discusses agomelatine (Valdoxan ™/Thymanax ™; Servier/Novartis), which is a melatonin (MT1/MT2) agonist and serotonin (5-HT2c) receptor antagonist. Agomelatine has been approved for the treatment of adults with major depression by several regulatory agencies and is now on the market in 41 countries. Areas covered: Literature related to agomelatine was reviewed on PubMed using the search terms 'agomelatine OR S-20098' and 204 articles were found. Twelve published, randomized, double-blind studies were included in this review. Expert opinion: Agomelatine produces strong effects on circadian sleep phase disturbances, improving time to sleep onset and quality of sleep. It has been shown to be superior to placebo and similar to existing antidepressants, as demonstrated by short-term clinical trials and one relapse prevention trial. However, 0 0.6% and 3 4.5% of patients treated with 25 and 50 mg, respectively, showed elevated transaminases. Although none of these reactions so far seem to have been serious, the adverse effects in the liver may present a regulatory and marketing challenge. Given equivalence or modest superiority to existing, generic alternatives, the acceptability in a third-party reimbursement environment is questionable. Future clinical trials are needed to establish an appropriate market niche.

KW - Agomelatine

KW - Antidepressant

KW - Anxiety

KW - Depression

KW - Melatonin receptors

KW - Serotonin receptors

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=80052931210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052931210&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.607812

DO - 10.1517/14656566.2011.607812

M3 - Article

C2 - 21916789

AN - SCOPUS:80052931210

VL - 12

SP - 2411

EP - 2419

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 15

ER -